800-680-7137Call For Help With Addiction
Talk To Someone Now
- Find a Clinic Near You
- Access Help and Resources
- Get 24-Hour Guidance and Information
SponsoredNo results found!
Medication treatment for opioid use disorder in Pittsburgh
Pittsburgh and the surrounding Allegheny County are served by both opioid treatment programs (OTPs) and office-based prescribers, so people looking for medication for opioid use disorder (MOUD) here usually have real choices close to home. The three FDA-approved medications, methadone, buprenorphine (including Suboxone), and naltrexone (including Vivitrol), are all available in the region, through daily-dosing clinics and through doctors’ offices and telehealth. The listings on this page show providers near you. If you are not sure where to start, the site’s helpline can point you toward a first call.
Your medication options, and where each one comes from
Understanding what the listings represent starts with the medications. Methadone for opioid use disorder is dispensed only through a licensed opioid treatment program, not a regular pharmacy, which is why OTPs (often called methadone clinics) anchor much of the local system. Buprenorphine works differently: since the federal X-waiver was removed in 2023, any clinician with a standard DEA registration can prescribe it, so you can get buprenorphine in a doctor’s office and fill it at a pharmacy, or receive it inside an OTP. It comes as buprenorphine-naloxone films and tablets and as a monthly extended-release injection (Sublocade). Naltrexone, including the monthly Vivitrol shot, is not a controlled substance and any licensed provider can prescribe it, but treatment starts only after you have been off opioids for a set time. Care happens in two settings: an opioid treatment program, which handles methadone and can offer the others, and office-based opioid treatment (OBOT), meaning a physician, nurse practitioner, or physician assistant who prescribes buprenorphine or naltrexone. If you want to think through the trade-offs first, it helps to see how methadone and Suboxone compare and to read the basics of how methadone treatment works. Your prescriber decides the right fit with you.
Starting treatment: what the first visit looks like
The first step is usually an intake assessment, where a provider reviews your history and, if medication is appropriate, plans how to begin (induction). Bring a photo ID and insurance information if you have them, though many programs will start the conversation without them. One timing detail matters with fentanyl: starting buprenorphine too soon after using can trigger sudden, severe withdrawal (precipitated withdrawal), so a clinician plans when to take the first dose rather than leaving it to chance. Because so much of the local drug supply has been fentanyl, this is worth asking about directly. Some Pittsburgh-area programs offer same-day or next-day starts, and telehealth can shorten the wait for buprenorphine. For more on the medical side of stopping fentanyl, see methadone treatment for fentanyl addiction.
Take-home doses, telehealth, and the current rules
Federal rules changed in ways that matter for anyone transferring in or returning to care. SAMHSA’s 2024 update to 42 CFR Part 8 expanded take-home methadone, up to a 28-day supply for patients who are stable in treatment, on a graduated schedule earlier on, with the program deciding eligibility based on your progress. The same update allowed treatment to start by telehealth and authorized mobile medication units. As of July 2026, buprenorphine can be started through telehealth, including by phone in many cases, without a prior in-person visit; those flexibilities run through the end of 2026 and are still being finalized, so confirm current options with a provider. Methadone for opioid use disorder is still started and dispensed through an OTP, and some programs can begin it with a telehealth visit. If you are moving here or switching programs, ask a clinic about transfers and guest dosing, and about why a steady methadone dose matters during a transition.
Paying for treatment in Allegheny County
Pennsylvania’s Medicaid program, called Medical Assistance, covers all three medications for opioid use disorder. Behavioral health benefits run through HealthChoices, delivered by county Behavioral Health Managed Care Organizations, so your MOUD care is typically coordinated through your assigned BH-MCO. If you are uninsured or worried about cost, Allegheny County’s Single County Authority can help arrange funding and placement, and OTPs commonly accept Medicaid, Medicare, private insurance, and self-pay, sometimes on a sliding scale. Federal SAMHSA block grant dollars also support treatment for people who cannot pay. Coverage details and any prior-authorization steps vary by plan, so it is worth confirming specifics with the provider or your plan before your first visit.
The overdose picture in Allegheny County, and why treatment is the response
The trend here has turned sharply. Allegheny County recorded 665 fatal accidental overdoses in 2023, which fell to 432 in 2024, with preliminary 2025 figures showing a further drop to 344 (Allegheny County records, reported February 2026). That brings the county’s overdose death rate to roughly half of its 2017 peak of 835 deaths. Fentanyl has driven most of these deaths, though Prevention Point Pittsburgh’s drug-checking found fentanyl in a declining share of samples sold as such, from about 85 percent three years ago to well under half in 2025, alongside the spread of the sedative medetomidine and of xylazine, neither of which naloxone reverses. Local officials credit wider naloxone availability, fentanyl test strips, and harm-reduction outreach for much of the decline. The takeaway for anyone reading this is straightforward: effective medication treatment exists in this county right now, and starting it is the single most protective step available. For background on the condition itself, see opioid addiction and how it is treated.
Overdose prevention and harm reduction across the city
Pittsburgh has a mature harm-reduction network worth knowing about whether or not you are ready to start treatment. Prevention Point Pittsburgh, the region’s longtime syringe services program, distributes naloxone (Narcan), provides fentanyl and xylazine test strips, offers wound care, and helps connect people to medication treatment. Naloxone is available over the counter, through pharmacies under Pennsylvania’s statewide standing order, and free by mail through NEXT Distro or from community organizations supplied by the state Overdose Prevention Program. Pennsylvania’s Good Samaritan provision, Act 139 (also called David’s Law), offers certain criminal and civil protections to someone who calls 911 in good faith to report an overdose, provided they stay with the person and cooperate, so fear of arrest should not stop a call for help. A return to use is a common, manageable part of recovery from a chronic condition, not a failure, and carrying naloxone is a reasonable safeguard for anyone who uses or is close to someone who does. Knowing the signs of an overdose is covered in this guide to recognizing and responding to an overdose.
Pregnancy, the justice system, and continuing care
Some situations carry added stakes. For pregnant patients, methadone and buprenorphine are the recommended standard of care, and staying in treatment is safer for both parent and baby than stopping; providers also plan for neonatal opioid withdrawal syndrome (NOWS) so it can be managed at birth. Pennsylvania uses a Plan of Safe Care to support the family rather than to punish, and treatment is confidential, points worth raising with a provider if fear of child-welfare involvement is holding you back. For people leaving the Allegheny County Jail, the facility operates a medication treatment program and connects people to a peer navigator and community care on release, which lowers the risk of overdose in the dangerous days after incarceration. Court-ordered and probation-related referrals are common, and many programs can provide the documentation these situations require. If you are helping a family member, this guide for families and information on methadone and pregnancy may help.
Common questions about MOUD in Pittsburgh
Do I have to go to a clinic every day for methadone?
At first, methadone usually means daily visits to an opioid treatment program. As you become stable, federal rules updated in 2024 allow take-home doses up to a 28-day supply, with the program deciding eligibility based on your progress. Buprenorphine and naltrexone do not require daily clinic dosing.
What is the difference between methadone and Suboxone?
Both treat opioid use disorder effectively. Methadone is dispensed through an OTP; Suboxone (a buprenorphine-naloxone product) can be prescribed in a doctor’s office and filled at a pharmacy. They suit different people, which is a decision to make with a clinician.
Can I start buprenorphine by telehealth in Pennsylvania?
As of July 2026, yes, in many cases, including by phone, without a prior in-person visit. These federal flexibilities run through the end of 2026 and are still being finalized, so confirm what is current when you call.
Will Medical Assistance cover my treatment?
Pennsylvania’s Medicaid program covers all three medications for opioid use disorder, with behavioral health delivered through county HealthChoices plans. Confirm any copay or prior-authorization details with your plan or the provider.
Is it safe to keep taking medication long term?
Long-term medication is legitimate, effective care, not an unfinished step. Many people stay on methadone or buprenorphine for years, and that decision belongs to you and your provider.
Last reviewed and disclosures
Last reviewed July 2026.
Sources
- Allegheny County (via CBS News Pittsburgh and Axios Pittsburgh), fatal accidental overdose counts, 2023 to 2025, reported 2025 to 2026.
- Prevention Point Pittsburgh drug-checking data (CBS News Pittsburgh, 2026).
- Allegheny County Opioid Settlement Annual Report, 2024.
- SAMHSA and DEA, telemedicine and buprenorphine prescribing rules (Fourth Temporary Extension and buprenorphine telemedicine final rule), 2025 to 2026.
- SAMHSA, 42 CFR Part 8 final rule, 2024.
- Pennsylvania Department of Drug and Alcohol Programs, naloxone standing order and Act 139 (Good Samaritan Law).
- Pennsylvania Department of Human Services and CMS state plan, Medical Assistance MOUD coverage.
- FDA and SAMHSA, medications for opioid use disorder overview.
Methadone Centers is a treatment-discovery and education resource, not a medical provider. We do not provide medical advice, diagnosis, or treatment. Always consult a licensed clinician about your care.
Some calls placed through this site may be answered by a sponsored treatment provider. This does not affect the information presented here.